Book by 22nd December 2009 to receive a £300 early bird discount

Book by 12th February 2010 to receive a £100 early bird discount

SMi present their 6th annual conference on

Asthma & COPD

Wednesday 21st &Thursday 22nd April 2010
London Marriott Hotel Regents Park, London

KEY SPEAKERS INCLUDE:

Peter Barnes
Head of Respiratory Medicine
Imperial College London
Chris Compton
Vice President, Respiratory Franchise
Novartis
Peter Howarth
Reader in Medicine and Head of Clinical Translational Research
University of Southampton
Matthew Catley
Senior Scientist
UCB Celltech
Julien Giovannini
Team Manager, Early Development
AstraZeneca
Mark Parry-Billings
Chief Executive Officer
Topigen Pharmaceuticals
Phillip Monk
Chief Scientific Officer
Synairgen

Explore the latest developments in
asthma & COPD drug design, find
new ways of improving clinical
trial models and discuss new
treatments
KEY TOPICS:
• New therapeutic targets in asthma and COPD
• Optimising respiratory clinical trial data
• Antibody-based biologics for the treatment of asthma
• Human in-vitro models as translational research tools
• Device options for delivery of oligonucleotides

SPONSORED BY: PLUS A HALF DAY PRE-CONFERENCE WORKSHOP

Tuesday 20th April 2010, London Marriott Hotel Regents Park, London

Device Possibilities for Future Inhaled Therapies

Workshop leader: Ola Nerbrink, Owner, Respiron Consulting
1.30pm – 5.30pm

www.smi-online.co.uk/2010asthma.asp
Register online and receive full information on all of SMi’s conferences
Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
Asthma & COPD
Day One Wednesday 21st April 2010 www.smi-online.co.
8.30 Registration & Coffee 12.20 Networking Lunch

9.00 Chairman's Opening Remarks 1.50 ANTIBODY BASED BIOLOGICS FOR THE TREATMENT OF ASTHMA
Peter Barnes, Head of Respiratory Medicine, Imperial College • Areas for antibody based biologics to make an impact in the clinic
London • Review of pre-clinical and clinical data
• Patient stratification
9.10 KEYNOTE ADDRESS:
• Future directions for biologicals in asthma
NOVEL MECHANISMS AND NEW THERAPEUTIC TARGETS IN
Matthew Catley, Senior Research Scientist, UCB Celltech
ASTHMA AND COPD
• Discuss progress in understanding asthma and COPD
• Similarities between COPD and severe asthma 2.30 IMPACT OF DRUG SUBSTANCE AND PRODUCT CHARACTERISTICS
• Developing biomarkers to aid drug development ON IN-VITRO PERFORMANCE
• What are the unmet needs? • Parameters affecting in-vitro and in-vivo performance
Peter Barnes, Head of Respiratory Medicine, Imperial College • Parameters affecting stability
London • How can these parameters be measured?
• Monitoring and control of parameters during development
9.50 COLLABORATION BETWEEN COMPANIES IN THE PRECOMPETITIVE Frank Thielmann, PDU Manager, Novartis
SPACE
Respiratory Calls Under the Innovative Medicines Initiative 3.10 Afternoon Tea
• Progress with the U-BIOPRED severe asthma and PROACTIVE
COPD consortia
3.40 EARLY PHARMACEUTICAL DEVELOPMENT:
• Areas for additional respiratory calls under the initiative
MAXIMISING PORTFOLIO DYNAMICS IN ASTHMA AND COPD
• Other opportunities for collaboration between companies in the
precompetitive arena • Understanding diversity of portfolio in early phase and CMC
Chris Compton, Vice President, Respiratory Franchise, Novartis implications
• Oral and inhalation key triggers for pharmaceutical development
10.30 Morning Coffee from lead optimisation to FIM/proof of principles
• Candidate drug selection, development and risk management
11.00 NOVEL AND EMERGING BRONCHODILATORS • Example of properties evaluation from small molecules to
• Role of bronchodilators in the treatment of asthma and COPD oligonucleotides
• The need for long-acting bronchodilators Julien Giovannini, Team Manager, Early Development, AstraZeneca
• Evidence from in vitro studies
• Emerging trends 4.20 PHASE 2 PROOF OF CONCEPT STUDIES FOR ASTHMA:
Alan Young, Associate Director and Principal Scientist, AstraZeneca WHAT ARE THE OPTIONS?
• Bronchoprovocation and other challenges/mechanistic type
11.40 OPTIMISING RESPIRATORY CLINICAL TRIAL DATA:
studies
RESPIRATORY CORLAB
• Quality checks for overall quality and repeatability • Clinical asthma POC studies
• Analysis of flow volume graph • Which design is best? Strategic, logistical and sample size
• Best test reviews considerations
• Query resolution and reporting Michael R. Hodges, Chief Medical Officer, Altair Therapeutics
Jim Sowash, Manager, Respiratory OverRead, CareFusion Research
Services 5.00 Chairman’s Closing Remarks and Close of Day One

Register online at www.smi-online.co.uk/2010asthma.asp • Alternativ

SPONSORED BY Activaero is the world leader in the design of controlled breathing drug delivery technologies that maximise the efficiency and precision of
inhaled drugs. These innovative technologies enable safer, more cost-efficient, and effective options for inhaled treatments of respiratory
diseases. As a centre of excellence in aerosol medicine, Activaero has a track record in supporting its partners in pre-clinical and clinical
projects for pulmonary drug development. The AKITA technology is also available commercially as AKITA® JET, a stand alone controlled
breathing device. In addition to AKITA technologies, Activaero markets Watchhaler™, a revolutionary children’s spacer that controls the
patient’s inhaled volume and flow-rate, and COAALA, an inhalation technology for use in preclinical lung studies. www.activaero.com

CareFusion Research Services (formerly Cardinal Health Research Services) is a global market leader providing customised hardware,
software and services to support all phases of clinical research. For respiratory, cardiac safety and any trial requiring electronic patient-
reported outcomes (ePRO), their inclusive solutions and dedicated experts provide you with complete support. CareFusion’s innovative
technology and services ensure the most accurate data and efficient trial management. www.carefusion.com

nSpire Health is a leading provider of respiratory diagnostic products and core lab services including PiKo®; the world’s first personal
respiratory home monitoring device. nSpire health develops and provides products and services for Lung Function Diagnostics, Diagnostic
Spirometry, Disease Management, Respiratory Clinical Trials, and Cardiopulmonary Exercise Testing to healthcare professionals
throughout the world. nSpire Health is committed to revolutionising the way the world detects and treats respiratory diseases.
www.nspirehealth.com

Vitalograph is a world leading provider of outstanding quality respiratory diagnostic devices, clinical trials and medical equipment
servicing. Their extensive respiratory range includes spirometers, peak flow meters, COPD screeners, asthma monitors, e-diaries, inhaler
trainers and resuscitation devices. With a pioneering heritage of excellence spanning half a century, Vitalograph continue to make valuable
contributions to effective medical care and enhanced quality of life. www.vitalograph.co.uk

Supported by
 Asthma & COPD
uk/2010asthma.asp Day Two Thursday 22nd April 2010

8.30 Re-registration & Coffee 12.20 Networking Lunch

9.00 Chairman's Opening Remarks 1.50 PUTTING PHOSPHORYLATION IN THE FRAME:

Peter Howarth, Reader in Medicine and Head of Clinical KINASES AS TARGETS FOR NEW THERAPIES
Translational Research, University of Southampton • Signalling roles of protein and lipid kinases
• Identification of kinase isoforms
9.10 EMERGING AREAS IN AIRWAYS DISEASE • Kinases as potential drug targets
• Respiratory microbiome • Kinase inhibition as an approach to suppression of airway
• Biomechanical forces inflammation and remodelling
• Structural influences Gordon Dent, Senior Lecturer in Pharmacology, School of Medicine,
• Small airways Keele University
Peter Howarth, Reader in Medicine and Head of Clinical
Translational Research University of Southampton 2.30 OLIGONUCLEOTIDES: NEW THERAPEUTIC APPROACHES FOR
ASTHMA AND COPD
9.50 DOSING AND TARGETING STRATEGIES FOR PULMONARY CLINICAL • Overview of the therapeutic class
TRIALS • Developments in targeting lung disease
• Parameters influencing lung dose of inhaled drugs
• Pre-clinical development: challenges and attributes
• Options to improve consistency in lung dose
• Emerging clinical data and product profiles
• Potential to improve quality of trial outcomes by controlled
Mark Parry-Billings, Chief Executive Officer, Topigen
inhalation
Pharmaceuticals
• Regulatory and commercial aspects of device selection during
different development stages
3.10 Afternoon Tea
Axel Fischer, Managing Director and Chief Operating Officer,
Activaero Technologies
3.40 HUMAN IN VITRO MODELS AS TRANSLATIONAL RESEARCH TOOLS
10.30 Morning Coffee • The need to improve the ability of preclinical models to predict
clinical outcome
11.00 TARGETING INFLAMMATION IN COPD • Focus on models of mechanisms relevant to asthma and COPD
• Lung cell models • Examples of use of models for both target identification and
• Corticosteroid insensitivity target validation
• Novel targets • Sourcing tissue and cells from subjects with lung diseases
• Clinical trial data Phillip Monk, Chief Scientific Officer, Synairgen
Dave Singh, Medical Director, Medicines Evaluation Unit, University
Hospital Of South Manchester NHS Foundation Trust 4.20 DNAZYM TECHNOLOGY FOR ASTHMA TREATMENT
• DNAzyme technology
11.40 LESSONS LEARNED IN CENTRALISED SPIROMETRY • Possible targets suitable for DNAzym approach
• Over reading systems – the pluses and minuses • Off-target effects
• Identifying abnormalities and their cause • Preclinical considerations
• Catching errors before they become issues Harald Renz, Head of Department of Clinical Chemistry and
• Case studies Molecular Diagnostics, University of Marburg
Aleck J. Harrison, Consultant Clinical Scientist, AJH Partners
Grant Sowman, Pulmonary Function Testing Specialist, Vitalograph 5.00 Chairman’s Closing Remarks and Close of Conference

ely fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

Who should attend?

Directors, Chief Executives and Senior Scientists
working in the following areas:
• Respiratory Science
• Research and Development
• Inflammation
• Regulatory Affairs
• Drug Discovery
• Respiratory Illness
• Inhalation Drug Delivery
• Clinical Trial Design
• Preclinical Development
• In-Vitro and In-Vivo Research
• Medical Devices
• Thoracic Medicine
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages,
uniquely tailored to complement your company’s marketing strategy.
Should you wish to join the increasing number of companies benefitting
from sponsoring our conferences please call: Alia Malick on +44 (0)20
7827 6168 or email: amalick@smi-online.co.uk
Want to know how you can get involved? Interested in promoting your
pharmaceutical services to this market? Contact Margaret Mugema, SMi
Marketing on +44 (0) 20 7827 6072 or email: mmugema@smi-online.co.uk
PHARMACEUTICAL
FORWARD PLANNER

JANUARY 2010
18/19 Models for Key Opinion Leader Management*
20/21 Pre-filled Syringes
24/25 Paediatric Clinical Trials
27/28 Electronic Laboratory Notebooks

FEBRUARY 2010
01/02 Biomarkers Summit
03/04 Adaptive Designs in Clinical Drug
Development
10/11 Parallel Trade
15/16 Stem Cells
22/23 Drug Design

MARCH 2010
10/11 Imaging in Oncology
15/16 Pharmacovigilance
17/18 Superbugs & Superdrugs
24/25 Accelerating Patient Recruitment in
Clinical Trials

APRIL 2010
21/22 Asthma & COPD
21/22 Computer Systems Validation
26/27 High Throughput Screening
28/29 Controlled Release

MAY 2010
10/11 Generics, Supergenerics & Patient
Strategies
17/18 Clinical Trial Logistics

JUNE 2010
07/08 Pain Therapeutics
14/15 KOL Europe*
17/18 Global Protein Summit
28/29 RNAi, siRNA & miRNA
28/29 Pharmaceutical Portfolio &
Product Lifecycle Management

JULY 2010
05/06 Clinical Trials in Cancer
06/07 ADMET
12/13 In Vitro Diagnostics

* These conferences will take place

in mainland Europe.

ABOUT THE SMI PHARMACEUTICAL TEAM

SMi have been involved in the pharmaceutical
industry since 1993 and have developed a series
of informative and niche events, covering the
latest issues and developments surrounding the
industry. Events bring together senior industry
professionals and serving companies who have a
focus on being at the forefront of developments in
this area. SMi aim to generate informed and
topical discussion through the medium of both
conferences and executive briefings. Our
pharmaceutical events are research-based and
content driven with regular contact with major
industry personnel and cover a wide range of
industry sectors. For more information, please
visit www.smi-online.co.uk/pharma.asp

Want to know how you can get involved?

Interested in promoting your
pharmaceutical services to this market?
Contact Margaret Mugema, SMi Marketing
on +44 (0) 20 7827 6072 or
email: mmugema@smi-online.co.uk
 HALF-DAY PRE-CONFERENCE WORKSHOP
Tuesday 20th April 2010
1.30pm – 5.30pm
London Marriott Hotel Regents Park

Device Possibilities for

Future Inhaled Therapies

In association with:

Inhalation devices used in asthma therapy have

continually evolved and should comprise of powder and
liquid devices with good performance. Future
development of these devices is still needed and their
performance will improve as the regulatory landscape
sharpens requirements. This follows a path taken by
the regulatory agencies but also will be an outcome of
new therapies with more sensitive API’s and a
subsequent need for better dosing accuracy and range.
This workshop will look into the options that are
available for future inhalation drug delivery. There will
be a strong focus on device/formulation interaction
possibilities and limitations along with some thoughts
on the patient interaction and patient interface
systems.

Workshop Agenda:
• What device options are there?
• Formulation considerations
• Performance possibilities and limitations
• Patient interaction

1.30 Registration and Coffee

2.00 Introduction

2.15 Device options

3.00 Formulation considerations for different

devices

3.45 Afternoon Tea

4.00 Device performance options and

limitations

4.45 Patient interaction and considerations

5.15 Conclusions

5.30 Close of workshop

About the Workshop Leader:

Dr. Ola Nerbrink has been active in the
pharmaceutical field for more than 24
years and is today the owner of Respiron
Consulting, a consultancy with a speciality
in early development of inhalation devices
and their interaction with formulation. He
was initially employed at AstraZeneca R&D, Lund,
Sweden in 1985 with focus on development and
characterisation of inhalation systems based on DPI’s,
nebulisers and pMDI’s, acquiring a broad knowledge
and business contact surface of the providers of
available inhalation technologies. From 2002 to 2009 he
was employed at Novo Nordisk in Hillerød, Denmark as
a specialist in inhalation systems. With his theoretical
and practical knowledge, Ola Nerbrink will give
attendees of this workshop a valuable insight into the
options and possibilities that exist in the future of
inhalation therapy.
 ASTHMA & COPD
Wednesday 21st & Thursday 22nd April 2010, London Marriott Hotel Regents Park, London Workshop: Tuesday 20th April 2010, London

4 WAYS TO REGISTER
www.smi-online.co.uk/2010asthma.asp
FAX your booking form to +44 (0) 870 9090 712 POST your booking form to: Events Team, SMi Group Ltd, Great Guildford
Business Square, 30 Great Guildford Street London, SE1 0HS, UK
PHONE on +44 (0) 870 9090 711

EARLY BIRD □ Book by 22nd December 2009 to receive a £300 off conference price
DISCOUNT □ Book by 12th February 2010 to receive a £100 off conference price

CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference and Half Day Workshop £1798.00 + VAT £2067.70
□ Conference only £1299.00 + VAT £1493.85
□ Half Day Workshop only £499.00 + VAT £573.85
Unique Reference Number

Our Reference LVU68 PROMOTIONAL LITERATURE DISTRIBUTION

□ Distribution of your company’s promotional
DELEGATE DETAILS literature to all conference attendees £999.00 + VAT £1148.85
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename: GROUP DISCOUNTS AVAILABLE

Surname: The Conference fee includes refreshments, lunch, conference papers and
Job Title: CD ROM containing all of the presentations.
Department/Division:
Company/Organisation:
VENUE London Marriott Hotel Regents Park, 128 King Henry's Road, London, NW3 3ST
Email:
Address:
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Town/City:
Post/Zip Code: Country: CD ROMS/DOCUMENTATION
Direct Tel: Direct Fax:
I cannot attend but would like to purchase the following CD ROMs/paper copy
Mobile: documentation: (Shipped 10-14 days after the event) Price Total
Switchboard: □ The Conference Presentations on CD ROM £499.00 + VAT £573.85
□ The Conference Presentations - paper copy £499.00 - £499.00
Signature: Date: (or only £300 if ordered with a CD ROM)
I agree to be bound by SMi's Terms and Conditions of Booking.

ACCOUNTS DEPT
Title: Forename:
PAYMENT
Surname: Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference U68 and the delegate’s name. Bookings within 7 days
Email: of event requires a credit card as guarantee. Please indicate method of payment:
Address (if different from above): □ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
Town/City: IBAN GB48 LOYD 3000 0900 9364 18
Post/Zip Code: Country: □ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
Direct Tel: Direct Fax:
All credit card payments will be subject to standard credit card charges.

Terms and Conditions of Booking Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
Payment: If payment is not made at the time of booking, then an invoice will be issued and must

CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
be paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested before entry to the event. CD ROMs will not be despatched until
payment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may Cardholder’s Name:
not ‘share’ a place at an event. Please make separate bookings for each delegate.

Cancellation: If you wish to cancel your attendance at a Conference and/or Briefing and you are
unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration Signature: Date:
charge, providing that cancellation is made in writing and received at least 28 days prior to the
start of the event. Regretfully cancellation after this time cannot be accepted. We will however I agree to be bound by SMi's Terms and Conditions of Booking.
provide the Conference documentation on CD ROM to any delegate who has paid but is unable to
attend for any reason. Due to the interactive nature of the Briefings we are not normally able to Card Billing Address (If different from above):
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or CD ROM as these are reproduced specifically to order. If we have to cancel
the event for any reason, then we will make a full refund immediately, but disclaim any further
liability.

Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.

Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □ we may also share your data with third parties
VAT
offering complementary products or services. If you have any queries or want to update any of the
data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk VAT at 15% is charged on the attendance fees for all delegates. VAT is also charged on CD
or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your ROMs and Literature Distribution for all UK customers and for those EU customers not
address on the attached letter.
supplying a registration number for their own country here: _______________________

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk